Atopic dermatitis (AD) is a highly prevalent chronic ... often negatively affect their day-to-day and long-term well-being. Lebrikizumab, a monoclonal antibody that inhibits an interleukin named ...

Eli Lilly had a lot riding on its two phase 3 trials of IL-13 inhibitor lebrikizumab in atopic dermatitis (AD) – and it now looks like it has backed a winner. The company has claimed across-the ...

Medscape Medical News, October 01, 2024 EADV 2024 Atopic Dermatitis Control on Biologic Persists Over 3 Years In a 3-year extension of the pivotal trials that provided lebrikizumab with an ...

In February 2024, the FDA put two Phase II studies of zelnecirnon under a clinical hold after a case of liver failure was deemed potentially related to the drug.

In addition, Thaçi added, the “safety data support the long-term use of nemolizumab for the treatment of adolescent and adult patients with moderate to severe atopic dermatitis.” The current ...

The South San Francisco, Calif., biopharmaceutical company in May shut down two trials of zelnecirnon, which was being evaluated as a treatment for asthma and atopic dermatitis.

Axicabtagene ciloleucel, known by the brand name Yescarta, has been accepted for treating adults with two types of blood cancer.

Long-term treatment of adolescents with moderate-to-severe atopic dermatitis (AD) with upadacitinib is safe and effective through 76 weeks, according to a study published online Oct. 23 in JAMA ...

Apogee Therapeutics' APG777 shows promise in treating atopic dermatitis with less frequent dosing. See why I rate APGE stock ...

Atopic dermatitis, also known as atopic eczema, is a chronic inflammatory familial disease of the skin. It is characterized by an increased ability to form immunoglobulin E and a tendency to ...

ZORYVE cream 0.15% is the first once-daily, Food and Drug Administration (FDA)-approved topical treatment for mild to moderate atopic dermatitis ZORYVE, a next-generation topical phosphodiesterase-4 ...

has recommended Ebglyss (lebrikizumab) for use in moderate to severe Atopic Dermatitis in the NHS England. On July 9th, 2024, the U.S. FDA approved Arcutis Biotherapeutics' ZORYVE® (roflumilast ...